3 Forgotten Small-Caps Under $10B Nobody Is Watching Right Now

Earnings season has been a full disaster-movie experience this week. $INTC down 20%, $AMZN sliding nearly 10%, Alphabet erasing hundreds of billions in market cap. Great television, genuinely terrible if you owned any of it. But while everyone was refreshing their AWS growth spreadsheets, a handful of smaller, weirder, more interesting companies were doing their thing in total silence. Let's fix that.

$ASTI (Ascent Solar Technologies) is a Colorado-based maker of ultra-lightweight, flexible thin-film solar panels, the kind you can literally laminate onto fabric, aircraft surfaces, or portable gear. With a market cap under $300 million, it barely registers as a rounding error on any institutional portfolio. What makes it interesting right now: the US military's interest in portable, off-grid power solutions has intensified with every news cycle about supply chain vulnerability and energy logistics. Ascent has existing Department of Defense relationships, and any formal contract expansion or new government procurement announcement could be a meaningful catalyst for a company this small. The bear case is real too: thin margins, dilution risk, and a long road to commercial scale. This is high-risk territory, but the upside asymmetry is the whole point.

$XPOF (Xponential Fitness) is the franchisor behind boutique fitness brands including Club Pilates, CycleBar, Pure Barre, and Row House. Market cap sits around $600 million, a fraction of where it was at its 2022 peak after a rough stretch of short-seller scrutiny and management turbulence. Here's the contrarian case: the company now has over 2,900 studios open globally, franchise fee revenue is recurring and relatively sticky, and international expansion (particularly in Asia-Pacific) is accelerating. With consumer spending on experiences holding up even as goods spending slips, Xponential's model has a structural tailwind. The catalyst to watch is any quarterly print that shows same-studio sales stabilization combined with margin recovery. Still a show-me story, but the setup is cleaner than 18 months ago.

$ARQT (Arcutis Biotherapeutics) is a dermatology-focused biotech out of Westlake Village, California, with a market cap around $900 million. It already has two FDA-approved products on the market, ZORYVE cream for plaque psoriasis and ZORYVE foam for seborrheic dermatitis, which puts it past the purely speculative binary-event phase most small biotechs live in. Revenue is growing but the street has mostly ignored it while chasing GLP-1 giants like $LLY. The specific catalyst here is the ZORYVE pipeline expansion, with additional indications in late-stage trials that could meaningfully widen the addressable market. The bear case is straightforward: commercial execution risk and a crowded derm market with entrenched competitors.

None of these are sure things. All three are genuinely small, genuinely underfollowed, and genuinely capable of going either direction in a hurry. But in a week when the entire investing world was staring at the same 10 tickers, that's kind of the point of looking somewhere else.